BSc3094 is a Tau aggregation inhibitor. BSc3094 may be utilized in Alzheimer's disease (AD) research.

Physicochemical Properties

Molecular Formula	C17H12N6O3S
Molecular Weight	380.38
Exact Mass	380.069
CAS #	946857-84-7
PubChem CID	25096749
Appearance	Yellow to orange solid powder
LogP	4.338
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	4
Heavy Atom Count	27
Complexity	553
Defined Atom Stereocenter Count	0
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	Tau aggregation[1]
ln Vivo	Sarkosyl-insoluble Tau is decreased by direct intraventricular injection of BSc3094 (3 mg/kg)[1]. By restoring the paired-pulse depression seen in pro-aggregant Tau slices that were not treated following the application of a paired-pulse stimulus of the Schaffer collaterals, BSc3094 rescues the pre-synaptic deficit in organotypic hippocampus slices from pro-aggregant animals. In rTg4510 mice, BSc3094 restores the increase in Tau phosphorylation levels to the baseline level. In rTg4510 mice, BSc3094 partially improved memory deficits[1].
Animal Protocol	Animal/Disease Models: Mice[1] Doses: 3 mg/kg Route of Administration: Iv Experimental Results: Direct intraventricular administration decreased sarkosyl-insoluble Tau. Animal/Disease Models: rTg4510 mice[1] Doses: 0.075~1.5 mM Route of Administration: Intraventricular administration Experimental Results: decreased the levels of sarkosyl-insoluble Tau in cortical extracts by ≈70%.
References	[1]. Inhibition of Tau aggregation with BSc3094 reduces Tau and decreases cognitive deficits in rTg4510 mice. Alzheimers Dement (N Y). 2021;7(1):e12170. Published 2021 Jun 1.

Solubility Data

Solubility (In Vitro)

DMSO: 33.33 mg/mL (87.62 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (6.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.6289 mL	13.1447 mL	26.2895 mL
	5 mM	0.5258 mL	2.6289 mL	5.2579 mL
	10 mM	0.2629 mL	1.3145 mL	2.6289 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.